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Background: In a recent study we showed that in patients with primary biliary cirrhosis (PBC) being positive or negative
for anti-M2 antibodies reacting with the 2-oxoacid-dehydrogenase complex (ODC) also antibodies to the beta- and
gamma-subunits of F1F0-ATPase (anti-β, anti-γ) occur. This is a mitochondrial enzyme but parts are also expressed on
plasma membranes of endothelial cells. Here we wanted to analyse in more detail their clinical relevance.
Methods: Fifty-nine untreated and histologically defined PBC patients who had been followed for at least five years
were included into the study (51 anti-M2 positive, 8 anti-M2 negative). Twenty-three of them were treated in the follow
up with ursodeoxycholic acid (UDCA), eight received during a trial methotrexate (MTX). In 13 patients orthotopic liver
transplantation (OLT) had to be performed. Serum samples before and during therapy were available. Patients were
analysed with respect to laboratory parameters, disease activity and histological stages.
Patients’ sera were tested by ELISA for IgG- and IgM-antibodies against the beta- and gamma-subunits which had been
recombinant expressed in E.coli and highly purified by electro-elution from SDS-gels after electrophoresis.
Results: Fifty-nine percent of the anti-M2 positive and 50% of the anti-M2 negative PBC patients had anti-β- and/or anti-
γ-antibodies. There were no differences between anti-β- and/or anti-γ-antibody positive or negative patients with
respect to biochemical parameters, immunoglobulins, histological stages or disease activity. Antibody reactivity
significantly decreased during UDCA and MTX-treatment and also after OLT.
Conclusions: Antibodies to the β- and γ-subunits of F1F0-ATPase occur in anti-M2 positive and –negative PBC but do
not have any relevance with respect to clinical activity or prognosis. However, in contrast to the anti-M2 antibodies they
decrease during UDCA and immunosuppressive therapy.
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Antimitochondrial antibodies are the hallmark in the diag-
nosis of primary biliary cirrhosis (PBC) [1]. Several subtypes
have been described [2], the most relevant being the anti-
M2 antibodies directed against the five subunits of the
2-oxoacid-dehydrogenase complex (ODC), the E2- and
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reproduction in any medium, provided the or(M2a, b), the E2-subunits of the 2-oxoglutarate deyhdro-
genase complex (OGDC) and the branched-chain 2-oxo-
acid dehydrogenase complex (BCOADC) (M2c) and the E1
alpha- and beta-subunits of the PDC (M2d, e) [3-7]. About
95% of PBC sera react with these subunits using either the
M2-antigen prepared from bovine heart mitochondria or a
fusion protein consisting of the E2-subunits of ODC, the
most important components [1,3,8-10]. However, in recent
years we observed in an increasing incidence the presence
of AMA as determined in the immunofluorescence test in
PBC sera which did not react with any of the subunits of
the ODC in ELISA or Western blotting [11]. In these seratd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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inner membrane enzyme namely the F1F0-ATPase, espe-
cially its subunits beta (anti-β) and gamma (anti-γ) [11,12].
Thus, 67% of anti-M2 negative PBC patients had anti-β-
and/or anti-γ-antibodies. Further analyses revealed that
they occur also in anti-M2 positive PBC in about 50%.
However, it turned out that they may be rather marker
antibodies for an autoimmune process in the liver in gen-
eral than specifically for PBC [12]. Despite this we wanted
to see whether these antibodies may correlate with any spe-
cific clinical or laboratory parameters in PBC, may be indi-
cative for an association with another (autoimmune) liver
process or are influenced by different therapeutic regimes.
Therefore, the present study was undertaken analysing
PBC patients who had been followed for five to 30 years.
Patients and Methods
Patients
Fifty-nine patients with clinically and histologically
defined PBC were included into the study (56 females, 3
males; mean age at time of diagnosis 48.7 years, range
19–63 years). Only patients who had been followed for
at least 5 years (range up to 30 years) at the Department
of Internal Medicine I were analysed. From each patient
2–30 consecutive serum samples were available (in total





Biochemical parameters: mean + SD (median)
AP (U/l) (normal < 120) 440 + 374 (309)
ASAT (U/l) (normal < 35) 38 + 43 (24)
ALAT (U/l) (normal < 35) 51 + 56 (26)
γGT (U/l) (normal < 50) 145 + 107 (129)
bilirubin (mg%) (normal < 1.5) 1,4 + 1,8 (1,0)
IgG-globulins (mg%) (normal < 1800) 1527 + 477 (1450)




Autoantibodies to: number (%)
mitochondria (IFT) 54 (92)
M2 (ELISA) 51 (86)
nuclear dots (sp100; IFT) 14 (24)
nuclear membrane (gp210; IFT) 4 (7)
centromeres 6 (10)
Significance between patients with inactive and active PBC: a) trend with p = 0.08; bDetailed clinical, biochemical, and serological data of
these patients are given in Table 1. Of the 59 patients,
54 (92%) had AMA in the immunofluorescence test
(IFT), 51 (86%) reacted with the M2-antigen containing
the five subunits of the ODC in the ELISA; i.e. 8 patients
were anti-M2 negative, and this was confirmed by tes-
ting them by Western blotting against the recombinant
ODC-subunits. Nevertheless, five of them showed the
typical AMA-pattern in the IFT.
Forty-five patients were at time of first diagnosis in stage
I/II, 14 in stage III/IV. Furthermore, the patients were
divided into two groups according to their clinical course
(active vs inactive): Group A (active course) consisted of 22
patients, who were at time of first diagnosis in late stages
or who were in stage I/II but developed within 5–10 years
signs of liver cirrhosis (histologically development of stage
III/IV, hyperbilirubinemia, portal hypertension, necessity of
liver transplantation, death because of liver failure); group
B (inactive course) included 37 patients who were at first
diagnosis in stage I/II and did not develop any signs of dis-
ease progression. Biochemical parameters of these two
groups are given in Table 1. Both groups differed signifi-
cantly with respect to ASAT and bilirubin levels, other bio-
chemical parameters were similar (Table 1).
None of these patients received any therapy at first
presentation at our department. Eight of them wereuntreated patients with PBC at time of first diagnosis
Inactive PBC Active PBC
n = 37 n = 22
36 20
1 2
344 + 250 (235) 647+519 (537)a)
34 + 48 (20) 46 + 28 (43)b)
43 + 53 (25) 62 + 62 (42)
128 + 86 (127) 194 + 146 (164)
0,8 + 0,7 (0,9) 2,3 + 2,8 (1,5)b)
1395 + 603 (1310) 1331 + 733 (1450)
298 + 162 (162) 398 + 290 (427)
37 8
0 14
33 (89) 21 (95)
31 (84) 20 (91)
9 (24) 5 (23)
1 (3) 3 (14)
2 (5) 3 (14)
) p < 0.05.
Table 2 Prevalence of antibodies to the β- and γ-subunits









β−subunit γ−subunit Number (%)
+ + 14 (27) 3 (38) 17 (29)
+ - 2 (4) 0 2 (3)
- + 14 (27) 1 (13) 15 (25)
- - 21 (41) 4 (50) 25 (42)
Analysis of 59 patients.
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in the course of a trial in the time between 1988 and
1989 when no other forms of therapy were available. Be-
yond 1994 all patients received ursodeoxycholic acid
(UDCA; 1000–1500 mg/day).
In 13 patients orthotopic liver transplantation had to
be performed. From these patients serum samples at dif-
ferent time points after transplantation were available
(0–6 months: n = 5; 6–12 months: n = 7; 12–24 months:
n = 5; > 24 months: n = 9).
As controls, sera from 41 healthy blood donors were
used (kindly provided by Prof. D. Wernet, Department
of Transfusion Medicine, University of Tuebingen).
Patients’ sera were stored at −20°C.
Sera from all patients had been taken for diagnostic
purposes. The study was approved by the local ethic
committee of the University Hospital Tuebingen.
Methods
Antigens and cell lines
For the immunofluorescence test (IFT) cryostat sections
from rat liver, kidney, stomach and heart were used [13]
as well as Chang liver cells for the demonstration of dis-
tinct antinuclear antibody (ANA) patterns.
The M2-antigen known to containing all five determi-
nants corresponding to the 2-oxoacid dehydrogenase
complex [3,6] was prepared from bovine heart mito-
chondria by chloroform release as described by Beechey
et al. [14] and Lindenborn-Fotinos et al. [15].
The recombinant PDC-E2, OGDC and BCOADC was
obtained from DIARECT AG (Freiburg, Germany).
The β− and γ-subunits of the F1F0-ATPase were
expressed in E.coli as recently described [12]. For further
purification and in order to avoid bacterial contaminations,
the recombinant proteins were applied to SDS-gel electro-
phoresis; after Coomassie-Blue-staining the relevant deter-
minants were excised and eluted as recently described [12].
Methods for detection of autoantibodies
IFT was performed for the demonstration of AMA accord-
ing to standardized methods [13] using cryostat sections
from rat liver, kidney, heart, and stomach as well as human
thyroid. Sera were diluted 1:10, titres > 1:40 were consid-
ered positive. Furthermore, sera were analysed by IFT on
cell cultures for the demonstration of different antinuclear
antibody specificities as reported [16].
Antibodies to M2, PDC-E2, OGDC and BCOADC
were detected by ELISA and Western blotting as previ-
ously described [6,11,12]. Anti-β and anti-γ antibodies
were determined only by ELISA because Western blot-
ting seems to be not a suitable method [12]. Briefly,
The highly purified recombinant β- and γ-subunits
obtained by electro-elution from the SDS-gels were
used for coating the microtiter plates at a concentrationof 8 μg/ml, patients’ sera were diluted 1:500. For the
visualization of bound autoantibodies, polyvalent pero-
xidase conjugated goat anti-human IgG- and IgM-
antibodies were used in parallel (IgG: dilution 1:3000,
IgM: dilution 1:2000; Dianova, Hamburg, Germany), as
substrate o-phenylenediamine was applied. Results were
given as absorbance multiplied by 1000.
Optimal antigen- and serum concentrations had been
evaluated by serial dilutions prior to the study.
Normal ranges for antibody reactivities with the anti-
gens were determined by analysis of sera from 41
healthy blood donors. Mean values of their absorbance
(× 1000) plus twice the standard deviation were
defined as cut-off values, and these cut-off values were
also confirmed by ROC (receiver operating curve) ana-
lysis (Additional file 1: Figure S1).
Statistics
Statistical analysis was performed with SSPS 19 using
the non parametric Mann–Whitney test for unpaired
and the Wilcoxon-test for paired groups. For the com-
parison of prevalences, the Chi square test was applied.
Results
Prevalence and reactivity of anti-β- and –γ-antibodies in
59 untreated PBC-patients at time of first presentation
Thirty-four (58%) of the 59 PBC patients had either anti-β-
or anti-γ-antibodies or both (Table 2). The antibodies were
of the IgG- as well as of the IgM-type (Table 3).
IgG antibody activity towards the β-subunit was signifi-
cantly higher in PBC patients as compared to healthy con-
trols, while IgM reactivity did not differ between both
groups (Figure 1). In contrast, both, IgG- and IgM-
antibody reactivity to the γ-subunit was significantly higher
in the PBC patients than in the healthy individuals.
Correlation of the different types of antimitochondrial
antibodies in 59 untreated PBC-patients at time of first
presentation
As demonstrated in Table 1, 92% of the 59 patients
showed the typical AMA-pattern in the IFT, but only 51







positive (n = 51) (n = 8) (n = 59)
number (%) positive
β−subunit IgG 11 (22) 1 (13) 12 (20)
IgM 9 (18) 2 (25) 11 (19)
γ−subunit IgG 16 (35) 2 (25) 18 (31)
IgM 23 (45) 3 (38) 26 (44)
Analysis of 59 patients with anti-M2 positive and –negative PBC.
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patients were negative for all five subunits of the ODC.
Five of them had AMA in the IFT, two had antibodies to
nuclear dots (sp100), two to centromeres, and none to
nuclear membrane (gp210). Of the eight anti-M2/ODC
negative patients, 4 (50%) had antibodies to the β- and/
or γ-subunit (Table 2). Comparing the reactivity of anti-




















p < 0.01 n.s.















Figure 1 Reactivity of antibodies to the β− and γ−subunits of F1F0-AT
patients and 41 healthy individuals were analysed. Individual values are givand –negative PBC, there was no statistically significant
difference between both groups (data not shown).
There was no correlation between antibody reactivity
towards M2/ODC and the β-subunit for IgG or IgM-
antibodies (r = 0.0002 and −0.03, respectively) or the
γ-subunit (r = 0.35 for IgG and r = −0.01 for IgM
antibodies). Fortyeight of the 59 sera (81%) reacted in the
Western blot with the M2a-determinant corresponding to
the E2-subunit of the PDC, but again there was no correl-
ation to the presence of anti-β- or anti-γ antibodies of the
IgG- or IgM-type (data not shown).
Correlation of anti-β− and –γ−antibodies with clinical and
histological parameters
There was no correlation of the presence or absence or
reactivitiy of antibodies to the β− and γ−subunit with
histological stages (Figure 2a, Table 4). Comparing
patients with an inactive and those with an active form
of PBC as defined in ‘patients’, again no significant diffe-
rences were observed in prevalence or reactivity of anti-
β− and/or-γ−antibodies (Figure 2b, Table 4).1)  PBC (n=59)  healthy (n=41)  PBC (n=59)  healthy (n=41)
p < 0.001 p < 0.001
γ-subunit IgG γ-subunit IgM
Pase in PBC-patients and healthy controls. Sera from 59 PBC
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Figure 2 Correlation of antibody reactivity to the β− and γ−subunit with histological (a) and clinical parameters (b). Data are shown as
means (bars) plus standard deviation and median (·).
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Table 4 Correlation of antibodies to the β− or γ−subunit
with histological stages and disease activity of PBC
Histological stages Disease activity








β−subunit γ−subunit Number (%)
+ + 12 (27) 5 (36) 10 (27) 7 (32)
+ - 1 (2) 1 (7) 1 (3) 1 (5)
- + 13 (29) 3 (21) 10 (27) 6 (27)
- - 19 (42) 5 (36) 16 (43) 8 (36)
Analysis of 59 patients.
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bilirubin, IgG-, IgA-, IgM-globulins) did not correlate
with antibodies to the β− or γ−subunit (not shown).
Influence of treatment on anti-β− and γ−antibodies
In a further step we wanted to see whether the antibodies
to the β− and γ−subunits are influenced by UDCA ther-
apy. In this analysis 23 patients were included, of whom
exact data on beginning of the therapy, dosage and com-
pliance were available and who were treated for at least
one year. From 11 of them sera were available within the
time interval one to two years and from 19 patients
within the interval two to four years after starting the
therapy. Seventeen of the 23 patients (74%) had anti-β−
and/or –γ−antibodies before treatment. The prevalence
significantly decreased to 45% (p < 0.01) being positive
after 1–2 and 58% (p < 0.05) after 2–4 year treatment.
There was also evidence for a decrease of anti-β- and
anti-γ reactivity (absorbance x 1000) during UDCA treat-
ment in those patients being positive before therapy,
which reached statistical significance despite the low
number of patients (Figure 3a, b).
In contrast, the prevalence and reactivity of anti-M2
antibodies was not influenced by this kind of treatment
(not shown).
Eight patients were also treated with methotrexate for
at least 5 months (range 5 months-13 years, median 14
months). Serum samples before treatment and at the last
time point during therapy were analysed. Five of these
patients (63%) had at least one of the two antibodies be-
fore therapy; at the last time point during therapy only
38% were still positive. Performing statistical analysis in
all 8 patients independently whether they were anti-β-
or –γ-positive before MTX-therapy or not, there was a
significant decrease in reactivity (absorbance × 1000)
during therapy (anti-β IgG: before therapy absorbance ×
1000: mean ± SD: 139 ± 26; median: 140; during ther-
apy: 108 ± 28; median: 100; p < 0.05; anti-β IgM: before
therapy: 166 ± 73; median: 136; during therapy: 131 ± 36;
median: 132; p < 0.05; anti-γ IgG before therapy: 248 ±
93; median: 223; during therapy: 171 ± 51; median: 156;p < 0.05; anti-γ IgM: before therapy: 149 ± 84; median
106; during therapy: 106 ± 53; median 91; p < 0.05).
However, analysing only those patients being positive be-
fore MTX-therapy, statistical analysis was not possible
due to the low number of patients.
In contrast, prevalence and reactivity of antibodies to
ODC (M2) were not significantly influenced by this
kind of treatment (IgG-antibodies: before therapy ab-
sorbance x1000: mean ± SD: 680 ± 425; median 769;
during therapy: 750 ± 456; median 845; IgM-anti-
bodies: before therapy 685 ± 411; median 535; during
therapy: 690 ± 353; median 575).
Anti-β− and –γ−antibody reactivity after OLT
In 13 patients liver transplantation had to be performed.
Nine of these patients had anti-β− and/or –γ−antibodies
before transplantation. The prevalence of IgG antibodies
and also their reactivity significantly decreased after
OLT (Figure 4), while IgM antibodies were not affected.
Similar data were obtained for the anti-M2 reactivity
(data not shown). Interestingly, there was one patient in
whom IgG reactivity to the b-subunit strongly increased
after OLT, and this patient had acquired hepatitis B at
that time.
Discussion
It is well known, that antibodies to the 2-oxoaciddehydro-
genase complex – previously named anti-M2 – are excel-
lent marker antibodies for the serological diagnosis of PBC
but that they do not correlate with any clinical, histological
or laboratory parameters, and that they are not influenced
by UDCA treatment and only transiently decrease after
liver transplantation [17]. Recently we described a further
AMA-type in PBC reacting with the β− and γ−subunits of
the inner mitochondrial membrane enzyme F1F0-ATPase
[11,12]. However, these antibodies were not restricted to
PBC but also found in patients with autoimmune (but not
viral) hepatitis and primary sclerosing cholangitis implying
that they may be a marker for an autoimmune liver process
in general. We, therefore, wanted to see whether this novel
antibody type may be indicative for distinct clinical sub-
types within the PBC patients, i.e. whether they may point
towards an association with another liver process. Analys-
ing a large group of PBC patients followed for a long time
period we observed, however, no correlation of anti-β− and
γ−antibodies with histological stages, disease activity, any
laboratory parameters, or an association with other auto-
immune processes, i.e. in this respect they resemble the be-
haviour of anti-ODC/M2 antibodies. But in contrast to
the anti-M2 antibodies, the anti-β− and γ−antibodies
decreased during treatment with UDCA and also during
immunosuppressive therapy as shown in the present study
for MTX – a phenomenon which is otherwise typical for
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n.s. p < 0.05 p < 0.05 n.s.
Figure 3 Influence of UDCA therapy on reactivity of anti-β (a) and –γ−antibodies (b). Only patients being positive for the respective
subunits before therapy are included. Individual values at the three time points are given. - = median.
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been designed in a period when uncontrolled studies
suggested that it may be effective in precirrhotic
PBC [18-22], but this is still controversially discussed
[23,24]. The number of our patients treated with
MTX was too low to allow any conclusions withrespect to its clinical efficacy; nevertheless it was of
interest that despite this low number of patients the
reactivities towards the β− and γ−subunits signifi-
cantly decreased.
IgG antibodies to the β− and γ−subunit also decreased










before OLT 0-6 months 6-12 months 12-24 months > 24 months before OLT 0-6 months 6-12 months 12-24 months > 24 months
Pat. 1 Pat. 2 Pat. 3 Pat. 4 Pat. 5 Pat. 6 Pat. 7 Pat. 8
Pat. 9 Pat. 10 Pat. 11 Pat. 12 Pat. 13 median
IgG-antibodies to the β-subunit IgG-antibodies to the γ -subunit
Figure 4 IgG-antibody reactivity of anti−β− and –γ−antibodies in 13 PBC patients before and after liver transplantation. Individual
values at the different time points are given. - = median.
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patients followed for several years whether this effect is
only transient.
We also confirmed that anti-β− and/or γ−antibodies
occur in about 50% of anti-M2 negative PBC [11], and
only some of them had AMA in the IFT; i.e. antibodies
to F1-ATPase are not closely related with a positive IFT
pattern as recently pointed out [11,12]. Hidden epitopes
may be responsible for this phenomenon using cryostat
sections in the IFT. Further, antibodies to the F1F0-
ATPase subunits did not correlate with anti-M2/ODC
reactivity or with the presence or absence of PBC spe-
cific antibodies to nuclear antigens such as gp210, sp100
or centromeres [25], indicating that they are an inde-
pendent phenomenon.
The induction of antibodies to F1F0-ATPase remains
still obscure; however, it has been shown that the F1F0-
ATPase is expressed on the cell surface of endothelial
cells, adipocytes, hepatocytes, and tumor cells, the F1-
domain facing outside [26-30]. Furthermore, compo-
nents of the F1F0-ATPase, usually the β-chain, have been
characterized as cell surface receptors for different
ligands involved in intracellular pH homeostasis, angio-
genesis, and lipid metabolites. Thus, apoA-I binds to
F0F1-ATPase expressed on endothelial cells and stimu-
lates proliferation of endothelial cells by promoting
extracellular ATP production [31]. Moreover, angiosta-
tin, an endogenous angiogenesis inhibitor also binds to
cell surface F1F0-ATPase on endothelial cells acting as
an inhibitor of cell proliferation [30,32]. It is, therefore,conceivable, that this plasma-membrane-exposed F1F0-
ATPase may become a neoantigen by binding of abnor-
mal ligands hereby developing into target for the
immune response. In this respect our preliminary obser-
vations are of interest indicating that also CD8+ T cells
recognizing especially the β-subunit exist, and that at
least the β-subunit seems to be expressed by cholangio-
cytes (unpublished observations). Interestingly, there
was one patient in whom IgG reactivity to the b-subunit
strongly increased after OLT in close relationship to the
acquisition of viral hepatitis B supporting the hypothesis
of neoantigen formation, probably induced by an infec-
tion. On the other hand, testing a large group of patients
with viral hepatitis (n = 110), only 12 had IgG anti-beta-
antibodies [12].
Conclusions
In conclusion we have shown that the antibodies to the β−
or γ−subunits of the F1F0-ATPase found in autoimmune
liver disorders in general do not have a distinct importance
in patients with PBC with respect to clinical, laboratory or
histological parameters or prognosis. Although their clin-
ical relevance is, therefore, at this moment limited, these
antibodies add to the plethora of autoantibodies in PBC
again underlining that its pathogenesis is not only PDC-E2
related. Quite on the contrary, also the F1F0-ATPase has to
be taken into consideration as a target antigen considering
the fact that it is not any more merely a mitochondrial en-
zyme but also exposed on plasma membranes serving as a
receptor for various ligands.
Nann et al. BMC Gastroenterology 2012, 12:152 Page 9 of 10
http://www.biomedcentral.com/1471-230X/12/152Additional file
Additional file 1: Figure S1. ROC curves for IgG- and IgM antibodies to
the β- and γ-subunit of F1F0-ATPase analysed with 59 sera from PBC
patients without therapy and sera from 41 healthy controls.
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